Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

The FDA Has Cleared Zymeworks' Investigational New Drug Application For ZW251, A Novel Glypican-3-targeted ADC Incorporating The Company's Topoisomerase 1 Inhibitor Payload, Zd06519, For Hepatocellular Carcinoma, the company plans to start Phase 1 studies for ZW251 in 2025

Author: Benzinga Newsdesk | July 28, 2025 06:09am

Posted In: ZYME